GeoVax Labs, Inc.
Monday, February 26, 2024
GeoVax is developing novel therapies and vaccines for solid tumor cancers and infectious diseases. The company’s lead program in oncology is a novel oncolytic solid tumor gene-directed therapy, Gedeptin®, presently in a multicenter Phase 1/2 clinical trial for advanced head and neck cancers. GeoVax’s lead infectious disease candidate is GEO-CM04S1, a next-generation COVID-19 vaccine targeting high-risk immunocompromised patient populations. Currently in three Phase 2 clinical trials, GEO-CM04S1 is being evaluated as a primary vaccine for immunocompromised patients such as those suffering from hematologic cancers and other patient populations for whom the current authorized COVID-19 vaccines are insufficient, and as a booster vaccine in patients with chronic lymphocytic leukemia (CLL). GEO-CM04S1 is also being evaluated in a Phase 2 clinical trial as a more robust, durable COVID-19 booster in healthy patients who previously received the mRNA vaccines.
CEO/Top Company Official
Lead Product in Development
GEO-CM04S1 - Next-Generation Covid vaccine. Gedeptin - Therapy for solid tumor cancers
Development Phase of Primary Product